Home › Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients
 

Keywords :   


Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients

2014-07-24 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: study phase patients prevention

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Dabbagh Named General Manager of Waldencast Ventures Glaze Brand
20.05BT scraps digital landline switch deadline
20.05Essie Introduces Nail Art Studio
20.05Ilia Beauty Introduces Vegan Lip Sketch Hydrating Crayon
20.05Summer interest rate cut possible, says Bank deputy
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Farm Progress America, May 20, 2024
More »